

# A mild catalyzed Imino-Diels Alder reaction.

## Synthesis of *N*-(2-(*o*-tolyl)-1,2,3,4-tetrahydroquinoline-4-il)formamide derivatives as antimicrobial agents

García Maza, L.<sup>1</sup>; Orosco Flórez, D.<sup>1</sup>; Mendoza Salgado, A.<sup>1</sup>; Rosales Rada, W.<sup>2</sup>; Mendoza Torres, E.<sup>2</sup>; Meléndez Gómez, C.\*<sup>1</sup>

<sup>1</sup>Grupo de Investigación en Química Orgánica y Biomédica, Universidad del Atlántico, Barranquilla, Atlántico.

<sup>2</sup>Grupo de Investigación Avanzada en Biomedicina, Universidad Libre, Barranquilla, Atlántico.

35<sup>o</sup> Congresso Latino-americano de Química e 61<sup>o</sup> Congresso Brasileiro de Química.  
14-18 November 2022 in Centro de Convenções do Hotel Windsor Florida, Rio de Janeiro, BRASIL.

### 1 Introduction


Multidrug-resistant gram-negative pathogens have emerged as etiologic agents of infectious diseases such as *Escherichia coli*<sup>1</sup>, and the microbial resistance to existing drug therapies reveals the need for new and efficient therapeutic agents<sup>2</sup>. Consequently, tetrahydroquinoline (THQ) alkaloids have appeared with remarkable pharmacological properties to develop novel antibacterial agents. The synthesis of THQs is described extensively in the literature through imino-Diels Alder reaction due to its simple, efficient, and low-cost preparation process<sup>3,4</sup>.

This study aims to explore the versatility of the iDA process with synthetic THQ derivatives as antibacterial agents against *E. coli*.

### 3 Results

#### Compound characterization


#### a *N*-(2-(*o*-tolyl)-1,2,3,4-tetrahydroquinoline-4-il)formamide synthesis through imino-Diels Alder (iDA) process.



**5a:** R<sub>1</sub>= R<sub>3</sub>= H; R<sub>2</sub>= F. **5b:** R<sub>1</sub>= R<sub>2</sub>= H; R<sub>3</sub>= C<sub>3</sub>H<sub>7</sub>. **5c:** R<sub>1</sub>= R<sub>3</sub>= H; R<sub>2</sub>= Me. **5d:** R<sub>1</sub>= R<sub>3</sub>= H; R<sub>2</sub>= Cl. **5e:** R<sub>1</sub>= R<sub>2</sub>= R<sub>3</sub>= H. **5f:** R<sub>1</sub>= R<sub>3</sub>= H; R<sub>2</sub>= I.


| THQ       | 5a | 5b | 5c | 5d | 5e | 5f |
|-----------|----|----|----|----|----|----|
| Rend. (%) | 56 | 24 | 71 | 44 | 42 | 56 |

#### b Coupling constants of <sup>1</sup>H-NMR. All compounds were supported by <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and two-dimensional NMR experiments.




**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):** δ 161.13 (C=O), 143.24 (C4'), 140.90 (C1'), 135.18 (C2'), 130.81 (C6'), 129.30 (C5'), 127.74 (C4'), 127.53 (C3'), 127.39 (C8'), 126.55 (C5), 125.59 (C7), 120.73 (C6), 114.91 (C8), 51.89 (C4), 45.12 (C2), 37.18 (C3), 20.54 (6-Me), 19.16 (2'-Me) ppm. **<sup>13</sup>C DEPT-135:** δ 161.13 (C=O), 130.79 (C6'), 129.30 (C5'), 127.74 (C4'), 127.49 (C3'), 126.55 (C5), 125.59 (C7), 114.91 (C8), 51.88 (C4), 45.12 (C2), **37.18 (C3)**, 20.54 (6-Me), 19.16 (2'-Me).


### 2 Workflow



#### c THQs inhibition percentage in *Escherichia coli* culture medium.



#### THQs (5a-f)



#### d MIC of evaluated molecules.

| THQ         | 5a | 5b | 5c | 5d | 5e | 5f |
|-------------|----|----|----|----|----|----|
| CMI (µg/mL) | 10 | 20 | 10 | 20 | 20 | 10 |

### 4 Conclusion

A series of 4-amide-THQ derivatives were obtained using an economical catalyst and under medium reaction conditions. In addition, compounds with electron-withdrawing groups could be considered growth inhibitors with MIC of 10 µg/mL, which deserves further investigation to explore the scope and limitation of their biological activities.

#### Bibliography:

- Dayal, N.; Opoku-Temeng, C.; Mohammad, H.; Abutaleb, N.S.; Hernandez, D.; Onyedibe, K.I.; Wang, M.; Zeller, M.; Seleem, M.N.; Sintim, H.O., *ACS Infect. Dis.*, **2019**, 5, 1820–1830.
- Rossolini, G.M.; Arena, F.; Pecile, P.; Pollini, S., *Curr. Opin. Pharmacol.*, **2014**, 18, 56–60.
- Meléndez Gómez, C.M.; Marsiglia, M.; Escarsena, R.; del Olmo, E.; Kouznetsov, V. V., *Tetrahedron Lett.*, **2018**, 59, 22–25.
- Salgado, A.R.M.; Galvis, C.E.P.; Kouznetsov, V. V.; Meléndez, C.M., *Curr. Org. Synth.*, **2021**, 18, 431–442.

**Acknowledgements:** L.J.G.M and \*C.M.M.G. thank to MINISTERIO and “el fondo de Investigación en Salud” (FIS) (CTel;519-2021 from 874-2020) for the financial support.